The total backlog in the clinical trials segment of Neuki, including SMO and CRO contracts, amounted to PLN 688.3 million as at June 30, the company announced.
“The areas of patient businesses and clinical trials achieved total sales revenues of PLN 428.6 million in the first half of the year (vs. PLN 222.2 million y/y). In the second quarter of 2023, the sale of plots exceeded PLN 210 million (+83%). In the clinical trials segment, for the first time, Neuca presented a combined backlog covering SMO and CRO contracts, which as at June 30 this year was amounted to PLN 688.3 million.
“Despite the only slightly declining growth rate of operating costs, the results obtained in the second quarter of the year are satisfactory. We maintain the direction set by our strategy. Most of the market changes introduced by the legislator will be conducive to this strategy. Neuca will cope with the remaining challenges thanks to its strong foundations, diversification skills and multi-directional development. We remain the most efficient company on the wholesale market, which is invariably confirmed by the constantly growing satisfaction of our customers,” commented Grzegorz Dzik, Vice-President, quoted in the material.
The Neuca Group is a market leader in the wholesale of medicines. The total share of the Neuca group companies in the domestic pharmaceutical wholesale market in Q4 2022 was 31.6%. The Group is also developing a network of medical clinics, is an expert in the clinical trials segment, implements telemedicine projects and invests in health insurance. The company is listed on the Warsaw Stock Exchange and is included in the mWIG40 index.